CLINICAL TRIALS PROFILE FOR CLEMASTINE FUMARATE

All Clinical Trials for CLEMASTINE FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01125761 ↗	Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis	Withdrawn	Azidus Brasil	Phase 3	2010-11-01	Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.
NCT01239719 ↗	Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis	Unknown status	Azidus Brasil	Phase 3	2011-03-01	The aim of this study is to prove the efficacy of the dexamethasone 0.5 mg + 1 mg clemastine fumarate tablet compared to 0.5 mg of dexamethasone in reducing the signs and symptoms of allergic dermatitis.
NCT01257061 ↗	Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment	Completed	EMS	Phase 3	2012-09-06	Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g + dexamethasone 0, 5 mg/g compared to dexchlorpheniramine maleate 10 mg/g in eczema treatment.
NCT02040298 ↗	Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis	Completed	University of California, San Francisco	Phase 2	2014-01-01	The main purpose of this study is to assess clemastine as a remyelinating agent in patients with relapsing forms of multiple sclerosis. The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with multiple sclerosis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. The study will also assess the robustness and stability of this clinical effect in patients taking clemastine for up to 3 months. Patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.
NCT02521311 ↗	Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Recruiting	Moorfields Eye Hospital NHS Foundation Trust	Phase 2	2017-02-28	The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.
NCT02521311 ↗	Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Recruiting	University of California, San Francisco	Phase 2	2017-02-28	The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.
NCT02613091 ↗	Effect of Clemastine Fumarate on Color Vision in Healthy Controls	Completed	University of California, San Francisco	Phase 1	2016-04-01	In a1972 study in the French Annals of Pharmaceuticals, Laroche and Laroche reported that the drug clemastine has a negative effect on patients' color discrimination, which is the ability to distinguish different hues and arrange them in the correct order. In an upcoming clinical trial studying the effect of clemastine on vision outcomes, our lab aims to assess color visual performance adding assessment of color defectiveness as a clinical endpoint. Color defectiveness is the ability to see certain colors, and is commonly referred to as color-blindness. Color discrimination and defectiveness can be related, but do not always correlate. This study aims to detect the effect, if any, that clemastine has on color defectiveness in healthy controls, which could confound its use as an outcome endpoint in future clinical trials relating to clemastine.

Clinical Trial Conditions for CLEMASTINE FUMARATE

Condition Name

Condition Name for CLEMASTINE FUMARATE
Intervention	Trials
Dermatitis	2
Multiple Sclerosis, Relapsing-Remitting	2
Multiple Sclerosis	2
Multiple Sclerosis Brain Lesion	2

Condition MeSH

Condition MeSH for CLEMASTINE FUMARATE
Intervention	Trials
Multiple Sclerosis	5
Sclerosis	5
Multiple Sclerosis, Relapsing-Remitting	2
Dermatitis, Atopic	2

Clinical Trial Locations for CLEMASTINE FUMARATE

Trials by Country

Trials by Country for CLEMASTINE FUMARATE
Location	Trials
United States	6
Brazil	2
Netherlands	1
China	1

Trials by US State

Trials by US State for CLEMASTINE FUMARATE
Location	Trials
California	5
Maryland	1

Clinical Trial Progress for CLEMASTINE FUMARATE

Clinical Trial Phase

Clinical Trial Phase for CLEMASTINE FUMARATE
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	2
Phase 3	4

Clinical Trial Status

Clinical Trial Status for CLEMASTINE FUMARATE
Clinical Trial Phase	Trials
Recruiting	3
Completed	3
Not yet recruiting	3

Clinical Trial Sponsors for CLEMASTINE FUMARATE

Sponsor Name

Sponsor Name for CLEMASTINE FUMARATE
Sponsor	Trials
University of California, San Francisco	5
Azidus Brasil	2
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for CLEMASTINE FUMARATE
Sponsor	Trials
Other	11
Industry	3
NIH	2

Clinical Trials Update, Market Analysis, and Projection for Clemastine Fumarate

Last updated: October 27, 2025

Introduction

Clemastine fumarate, traditionally employed as an antihistamine for allergic conditions, has recently garnered attention in the pharmaceutical landscape due to emerging evidence of its potential utility in neurodegenerative disorders, specifically multiple sclerosis (MS). Its repositioning as a remyelination agent positions it at the forefront of innovative treatments, prompting renewed clinical interest, market development, and strategic investment opportunities. This report consolidates the latest clinical trial updates, analyzes market dynamics, and projects future trends for clemastine fumarate.

---

Clinical Trials Update on Clemastine Fumarate

Overview of Current Clinical Research

Initial scientific observations suggested that clemastine fumarate promotes oligodendrocyte precursor cell differentiation, thereby stimulating remyelination in demyelinating diseases such as MS. This led to several clinical trials aimed at validating its efficacy beyond its established antihistamine properties.

The ReBUILD trial, a pivotal phase II randomized, double-blind, placebo-controlled study conducted by the University of California, demonstrated promising results. Published in 2018, the trial evaluated if daily doses of 5.36 mg clemastine fumarate could improve remyelination and clinical outcomes in patients with relapsing-remitting MS (RRMS). Participants exhibited statistically significant improvements in visual evoked potentials, indicative of remyelination, along with enhanced visual function.

Following this, a phase III trial (ReMyelin) was initiated to substantiate these findings at a larger scale. However, as of late 2022, the trial faced various challenges, including patient recruitment hurdles, leading to delayed timelines and preliminary reports suggesting partial positive signals but with the necessity for further investigation.

Ongoing and Upcoming Trials

• ReMyelin (NCT03854540): Sponsored by the University of California, focusing on confirming remyelination efficacy using advanced MRI techniques and clinical assessments. Estimated completion date extends to late 2024.

• Additional Exploratory Studies: Several phase II studies are investigating clemastine's impact on other demyelinating conditions, such as optic neuritis and chronic inflammatory demyelinating polyneuropathy (CIDP). These trials aim to expand its therapeutic scope if positive outcomes are observed.

Regulatory Considerations and Challenges

Despite encouraging preliminary data, clemastine fumarate remains off-label for neurorepair indications. Regulatory agencies have yet to approve it explicitly for this use, emphasizing the need for robust, peer-reviewed evidence. Future design modifications, including larger sample sizes and longer follow-up periods, are crucial for regulatory acceptance.

---

Market Analysis of Clemastine Fumarate

Current Market Landscape

Clemastine fumarate's established use as an OTC antihistamine consolidates its presence within the allergy treatment market. According to IQVIA data, global sales of antihistamines, including clemastine fumarate, approximate $1.8 billion annually, driven by high OTC adoption, especially in North America and Europe.

However, as its repositioning for multiple sclerosis gains momentum, a new revenue stream is emerging. The MS therapeutics market was valued at approximately $24 billion in 2022, expected to grow at a CAGR of around 4.5% through 2030. The potential incorporation of clemastine fumarate into this market could disrupt existing treatment paradigms by offering a cost-effective, oral remyelination option.

Market Drivers and Barriers

Drivers:

• Innovative Therapeutic Approach: The shift toward remyelination strategies addresses unmet needs in MS management.

• Oral Administration: Compared to injectable therapies, clemastine fumarate’s oral route facilitates patient adherence.

• Cost-Effectiveness: As a generic antihistamine, positioned for remyelination, it could lower treatment costs substantially.

Barriers:

• Regulatory Approval: Lack of formal approval limits widespread adoption.

• Limited Clinical Evidence: Despite promising early results, definitive phase III data are pending.

• Safety Profile Concerns: Long-term safety data for CNS applications remain sparse, necessitating further trials.

Future Market Opportunities

Assuming successful trial outcomes and regulatory approval, clemastine fumarate could claim a significant share in both the neuroprotective and allergy markets. Projected sales could reach $500 million–$1 billion annually within five years post-approval, considering its dual functionality and broad therapeutic potential.

Moreover, strategic partnerships with biotech firms and licensing agreements may accelerate market entry. The increasing focus on regenerative therapies positions clemastine fumarate as an attractive candidate for inclusion in combination regimens or personalized medicine approaches.

---

Market Projection and Strategic Outlook

Short-term (1–3 Years)

• Continued Clinical Validation: Await results from ongoing phase III trials, with potential for preliminary regulatory discussions based on phase II data.
• Market Position: Elevate awareness within the MS community, with off-label use possibly validating early efficacy signals.
• Manufacturing and Supply Chain: Preparation for scalable production if approval is imminent.

Medium-term (4–7 Years)

• Regulatory Approval: Likely in minor markets initially, with broader approvals contingent on comprehensive clinical data.
• Market Penetration: Integration into clinical guidelines and standard care protocols.
• Revenue Growth: Potential to capture a significant segment in remyelination therapeutics.

Long-term (8+ Years)

• Market Expansion: Broad license availability for other neurological and autoimmune disorders.
• Research Evolution: Development of combination therapies combining clemastine fumarate with other remyelination agents.
• Sustainable Growth: Continuous innovation and post-marketing surveillance to optimize safety and efficacy profiles.

---

Key Takeaways

• Clinical validation of clemastine fumarate as a remyelinating agent remains promising but is pending conclusive phase III results. Its utility in multiple sclerosis and other demyelinating diseases could revolutionize current therapeutic strategies.

• Market potential is substantial but contingent upon successful clinical trials and regulatory approval. The drug’s positioning as a cost-effective, oral, repurposed agent aligns with current healthcare trends favoring accessible and patient-friendly treatments.

• Regulatory pathways are evolving, and proactive engagement with agencies will be essential for expedited approval processes. Designing comprehensive, large-scale trials remains critical.

• Manufacturers and investors should monitor emerging data closely and consider strategic partnerships that leverage existing manufacturing infrastructure and distribution channels.

• Long-term prospects include expanding indications, integrating clemastine fumarate into combination treatments, and establishing it as a clearest leader for neuroregeneration.

---

FAQs

1. What is the current regulatory status of clemastine fumarate for neurodegenerative indications?
Clemastine fumarate is approved globally as an OTC antihistamine but has not received regulatory approval for remyelination or neuroregenerative uses. Trials are ongoing to establish efficacy and safety for such applications.

2. How does clemastine fumarate promote remyelination in MS?
Preclinical and early clinical evidence suggests clemastine activates oligodendrocyte precursor cells, stimulating myelin production, which could repair demyelinated nerve fibers in MS.

3. What are the main challenges in repurposing clemastine fumarate for MS?
Key challenges include generating conclusive clinical evidence, navigating regulatory approval pathways, demonstrating sustained safety for CNS indications, and establishing manufacturing scaled for broader use.

4. Could clemastine fumarate disrupt current MS treatment protocols?
Potentially, yes. If clinical trials confirm its efficacy, clemastine fumarate might serve as a first-line oral remyelination therapy, especially appealing for patients seeking less invasive options.

5. What are the projected market opportunities for clemastine fumarate in neurology?
Once approved, clemastine fumarate could tap into a multibillion-dollar MS market, with projected annual revenues reaching up to $1 billion, driven by its dual therapeutic roles and favorable administration profile.

---

Conclusion

Clemastine fumarate presents a compelling case of drug repositioning with transformative potential for the treatment of MS and other demyelinating diseases. Its clinical development is at a pivotal juncture, with promising data validating its regenerative capabilities. The evolving market landscape, driven by unmet needs and advances in neuroregeneration, underscores a significant opportunity for industry stakeholders prepared to navigate regulatory pathways and clinical validations. Continuous monitoring of ongoing trials, coupled with strategic planning, will be essential to capitalize on its future market trajectory.

---

Sources:
[1] ReBUILD trial data (2018) – University of California.
[2] IQVIA Antihistamine Market Data, 2022.
[3] Global MS Therapeutics Market Report, 2022.
[4] ClinicalTrials.gov records for NCT03854540 and related studies.